Randomised controlled trialcited by the Tayebat archiveabstract only checked★ key study A-CHM-05 standard review
Adding trastuzumab to chemotherapy halved recurrence in HER2-positive breast cancer
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Overview
Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122
Fewer recurrences and a third fewer deaths; serious heart problems in about 3-4 in 100 treated women.
Does the study support the specific claim? Partly · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Test trastuzumab added to chemotherapy.
- How was the study done?
Two RCTs analysed jointly.
- How many people, animals or samples were studied?
Operable HER2+ breast cancer.
- What was actually found?
HR 0.48 for events; 33% fewer deaths.
- How large was the observed effect?
+12% absolute DFS at 3 years.
- What do the results mean in everyday life?
Benefit clearly exceeds the cardiac risk for most patients; heart monitoring is needed.
- What are the study's limitations?
Interim analysis.
- What does it say about Elawady's specific claim?
Documents harm and much larger benefit.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That treatment should be avoided.
Scientific in-depth review
1. Full reference
- Authors
- Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N
- Journal
- N Engl J Med
- Year
- 2005
- Identifier
- PMID 16236738 DOI 10.1056/NEJMoa052122
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract | Grants: NCI NIH HHS
2. Research question
Does adding trastuzumab to adjuvant chemotherapy improve outcomes in HER2-positive breast cancer?
3. Study design and population
- Study design
- Randomised controlled trial – Joint analysis of two randomised controlled trials (NSABP B-31, NCCTG N9831)
- Population
Women with surgically removed HER2-positive breast cancer
- Country
USA/Canada (NSABP, NCCTG)
- Period
Interim analysis March 2005
- Sample size
Not stated as total in abstract; 394 events at interim analysis
- Inclusion and exclusion criteria
Operable HER2-positive breast cancer
4. Methods and endpoints
- Exposure / intervention
AC followed by paclitaxel plus 52 weeks trastuzumab
- Comparator
AC followed by paclitaxel alone
- Endpoints
Disease-free survival, overall survival, cardiac events
- Statistical methods
Hazard ratios; interim analysis
5. Actual results
- Results
Events 133 (trastuzumab) vs 261 (control); HR 0.48 (P<0.0001); absolute DFS difference 12% at 3 years; 33% reduction in risk of death (P=0.015). 3-year cumulative incidence of class III/IV CHF or cardiac death 4.1% (B-31) and 2.9% (N9831) in trastuzumab group.
- Absolute risks
DFS +12% absolute at 3 years; severe cardiac events 2.9-4.1% at 3 years
- Authors' conclusion
Trastuzumab with paclitaxel after AC improves outcomes in HER2-positive breast cancer.
6. Strengths
- Randomised
- Large effect
- Cardiac safety reported
7. Weaknesses
- Interim analysis (early stopping can overestimate effect)
- Joint analysis amended post hoc
8. Risk of bias
- Orienting tool
- RoB 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Early stopping at interim; open-label.
9. Assessment of the statistical interpretation
Large, highly significant benefit; cardiac harm real but much smaller in absolute terms than the gain in DFS.
10. Relevance to the specific claim
Shows both a cardiac harm and a large benefit in the same trial.
11. Independent contrary findings
Itself.
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
A benefit trial cited in a harms list; context omitted.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | some concerns |
| Precision of results | high |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | taken out of context |
14. Open questions
None for this purpose.
15. Linked fact checks
- Anthracycline chemotherapy (and chest radiotherapy) can cause chronic, dose-dependent heart damage that may appear or progress years after treatment. – Studies with mixed or unclear results
- The archive's 19 chemo/radiation studies are presented on the homepage as 'scientific studies confirming what Dr. Diaa proposed'; the harm-only study selection implies that the harms of chemotherapy and radiotherapy outweigh their benefits. – Studies contradicting or limiting the claim
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Listed in the bibliography of 'Harms of chemotherapy and radiotherapy' without interpretation.
- A. What was actually studied?
Benefit and cardiac safety of adjuvant trastuzumab.
- B. What did the authors find?
Recurrence/death hazard halved (HR 0.48), deaths reduced by a third; severe cardiac events in 2.9-4.1%.
- C. What conclusions do the authors themselves draw?
Trastuzumab improves outcomes.
- D. What does the archive derive from it?
Implied evidence of cardiotoxicity.
- E. Is this derivation scientifically justified?
Only partly: the trial documents cardiotoxicity, but its main result is a large survival benefit that the archive does not mention.
- Adequacy of the interpretation (by the archive)
- taken out of context